Why Global PH Matters

Pulmonary hypertension is common worldwide. Pulmonary arterial hypertension, it’s rarest and most severe form, is uncommon but disproportionately lethal.

≈1% of the global population may be affected by pulmonary hypertension

≈10% prevalence in adults over age 65

192,000 prevalent cases of PAH worldwide (2021)

22,000 deaths attributed to PAH globally in 2021

A Global Burden with Regional Fingerprints

Worldwide, PH is driven mainly by left-heart and lung disease. In low- and middle-income countries, a distinct set of infectious, hematologic, and environmental causes adds substantially to the burden.

Predominant Global Drivers

Left-heart disease
Chronic lung disease and hypoxia
Congenital heart disease
Chronic thromboembolic disease
Infections

Additional Drivers in LMICs

Rheumatic heart disease
HIV infection
Schistosomiasis
Sickle cell disease
Tuberculosis
High-altitude exposure

Where the Global PH Care Pathway Breaks Down

Delayed Diagnosis

Non-specific symptoms and low awareness push confirmation years past symptom onset

Limited Access to Echo/RHC

Echocardiography and right-heart catheterization remain scarce outside major centers.

Poor Referral Pathways

No standardized route for primary care to specialist PH evaluations.

Lack of PH-Trained Teams

Few multidisciplinary teams with dedicated PH expertise, especially outside referral hubs.

Unequal Access to PAH Therapy

Approved therapies remain unavailable, unaffordable, or unreimbursed in much of the world.

Trial and Registry Underrepresented

Patients outside North America and Europe are largely absent from pivotal evidence.

Sparse Regional Data

Limited epidemiologic data from Latin America, Africa, Asia and high-altitude populations.

A Center of Excellence Connects Every Step of PAH Care

Patient-centered care, strengthened by collaborations and continuous learning.

PAH Center of Excellence

Referral pathways
Accurate diagnosis and risk stratification
Multidisciplinary care team
Treatment access

Continuous Learning System

Registries
Clinical Trials
Education and Training

Precision Solutions

Earlier diagnosis
Individualized care
Equitable access
Better outcomes